Aanjaay Industries Limited

(Formerly known as Kabra Drugs Limited)

CIN NO : L02423MP1989PLC005438

Regd Off: 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh – 452 011. Phone : +91 9884624100

Date: 12th August 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers
21st Floor, Dalal Street
Mumbai – 400001

BSE Scrip Code: 524322

Sub: Financial Results for the quarter ended 30th June 2026 under Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to the provisions of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e 12th August 2026 has Considered and approved the un-audited financial statements for the quarter ended 30th June 2026 along with the limited review report of the Statutory Auditors of the Company.

The meeting of the Board of Directors of the Company commenced at 05.00 p.m. (IST) and concluded at 06:30 p.m. (IST).

Kindly take the aforesaid information on record and oblige.

Thanking you,

Yours sincerely,

For Aanjaay Industries Limited

(Formerly known as Kabra Drugs Limited)

NANJAPPAN ARAVIND

Digitally signed by NANJAPPAN ARAVIND
Date: 2026.08.12 18:50:55 +05'30'

AANJAAY INDUSTRIES LIMITED

Nanjappan Aravind
Managing Director
DIN: 01895602

Aanjaay Industries Limited
(Formerly known as Kabra Drugs Limited)
CIN:- L02423MP1989PLC005438
Regd Offc: 208 Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh, India, 452011

(Amount in ₹ Lakhs)

Statement of Unaudited Standalone Financial Results for the Quarter Ended June 30, 2026

		Quarter Ended			Year Ended
Sl No.	**Particulars**	**30th June, 2026**	**31st March, 2026**	**30th June, 2025**	**31st March, 2026**
		(Unaudited)	**(Audited)**	**(Unaudited)**	**(Audited)**
	INCOME				
1	Revenue from Operations	4,621.68	3,540.60	715.00	9,274.00
2	Other Income	7.65	11.31	1.62	49.27
3	**Total Income**	**4,629.33**	**3,551.91**	**716.62**	**9,323.27**
	EXPENSES				
(a)	Cost of materials consumed	-	-	-	-
(b)	Purchases of Stock-in-Trade	4,903.20	208.80	675.00	8,366.40
(c)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	(603.00)	3,097.80	-	-
(d)	Employee benefit expense	23.72	34.56	37.81	146.59
(e)	Finance Costs	0.53	1.47	-	3.00
(f)	Depreciation and amortization expense	2.06	1.75	0.34	7.11
(g)	Other expenses	18.81	65.50	53.46	228.10
4	**Total Expenses**	**4,345.32**	**3,409.89**	**766.60**	**8,751.20**
5	**Profit / (Loss) from operations before exceptional items Tax (3-4)**	**284.01**	**142.02**	**(49.98)**	**572.07**
6	Exceptional Items	-			-
7	**Profit / (Loss) before Tax (5 ± 6)**	**284.01**	**142.02**	**(49.98)**	**572.07**
	Tax Expense				
	Current Tax	71.73	35.54	-	75.54
	Deferred Tax Liability	(0.02)	0.14	-	0.55
	Prior Period Tax Reversal			-	-
8	**Total Tax Expenses**	**71.71**	**35.69**	**-**	**76.09**
9	**Net Profit / (Loss) after Tax (7 - 8)**	**212.30**	**106.33**	**(49.98)**	**495.98**
10	Other Comprehensive Income (net of tax)				
A	(i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
B	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
11	**Total Comprehensive Income for the period (9 ± 10)**	**212.30**	**106.33**	**(49.98)**	**495.98**
12	Paid-up equity share capital (Face Value of Rs.10/- each)	**2,370.79**	**2,370.79**	**2,370.79**	**2,370.79**
13	**Earnings Per Share (of Rs. 10/- each) (not annualised):**				
	(a) Basic	0.90	0.45	(0.21)	2.09
	(b) Diluted	0.90	0.45	(0.21)	2.09

Notes:

1. The above results which are published in accordance with Regulations 33 of SEBI (Listing Obligation & Disclosure Requirements), 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on August 12th, 2026. The Statutory Auditors have carried out a limited review of the above financial result.
2. These financial results have been prepared in accordance with Ind AS 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.
3. As the Company collectively operates only in one business Segment, hence, it is reporting its results in single Segment. Therefore, segment disclosure is not applicable.
4. The Company does not have any subsidiary/ associate/ joint venture entity(ies) for the respective period.
5. EPS is not annualized for the Quarterly results. The EPS has been computed based on weighted average number of equity shares outstanding for the respective periods
6. The figures for the corresponding previous periods / year have been regrouped / reclassified wherever necessary.
7. There were no exceptional and extra-ordinary items for the reporting period.
8. The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2026 and the published year-to date figures up to the quarter ended December 31, 2025, which were subjected to limited review.

For and on Behalf of the Board of directors of
Aanjaay Industries Limited
(Formerly known as Kabra Drugs Limited)

AANJAAY INDUSTRIES LIMITED

NANJAPPAN ARAVIND
Digitally signed by NANJAPPAN ARAVIND
Date: 2026.08.12 18:51:15 +05'30'

Nanjappan Aravind
Managing Director
DIN: 01895602

Place : Chennai
Date : 12.08.2026

CA INDIA

P P N AND COMPANY
CHARTERED ACCOUNTANTS

No.2, IV Cross Street, Sterling Road, Nungambakkam, Chennai - 600034.
(Near to Loyola College) Ph : 044 - 2828 0033, Cell : 98847 46227
E-mail : info@ppnaco.com | Web : www.ppnaco.com

Independent Auditor's Limited Review Report on unaudited standalone financial results of Aanjaay Industries Limited (Formerly known as Kabra Drugs Limited) for the quarter ended 30th June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors,
AANJAAY INDUSTRIES LIMITED,
(Formerly known as Kabra Drugs Limited)
Regd Offc: 208 Swadesh Bhavan, 2 Press Complex, AB Road, Indore,
Madhya Pradesh, India, 452 011

1. We have reviewed the accompanying statement of unaudited Standalone Financial Results of **AANJAAY INDUSTRIES LIMITED** ("the Company"), for the Quarter ended 30th June 2026 ("the Statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations 2015 as amended from time to time ("the Listing Regulations").

2. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ("Ind As 34 "Interim Financial Reporting") prescribed under section 133 of the Companies Act 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

3. Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Companies Act 2013 and consequently does not enable us to obtain assurance that we would be aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

P P N AND COMPANY * CHENNAI * CHARTERED ACCOUNTANTS

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Yours faithfully

For M/s. P P N And Company,
Chartered accountants
ICAI Firm Reg. No.: 013623S
Peer Review Certificate No.: 020690

DHARMICHAND HITESH
Digitally signed by DHARMICHAND HITESH
Date: 2026.08.12 18:45:38 +05'30'

P P N AND COMPANY * CHENNAI * CHARTERED ACCOUNTANTS

D. Hitesh
Partner
Membership Number: 231991
UDIN: 26231991YPRHAS8852

Place: Chennai
Date : 12-08-2026

Date: 12th August 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers
21st Floor, Dalal Street
Mumbai – 400001

BSE Scrip Code: 524322

Sub: Undertaking for Non- Applicability of Regulation 32 of SEBI (LODR) Regulations, 2015 for the quarter ended on 30th June 2026.

Dear Sir/Madam,
As per Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the listed entity shall submit to the stock exchange the following statement(s) for quarter ended on 30th June 2026 for public issue, rights issue, preferential issue etc. –

(a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable;

(b) Indicating category wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable and the actual utilization of funds.

In view of the aforesaid, I, the undersigned, Mr. Nanjappan Aravind, Managing Director of Aanjaay Industries Limited (Formerly known as Kabra Drugs Limited) hereby certify that Compliances of Regulation 32 of SEBI (LODR) Regulations, 2015 is not applicable to the company as the company has not issued any share by way of public issue, right issue, preferential issue etc. for the quarter ended on 30th June 2026.

Kindly take the aforesaid information on record and oblige.

Thanking you,

Yours sincerely,

For Aanjaay Industries Limited

(Formerly known as Kabra Drugs Limited)

NANJAPPAN ARAVIND
Digitally signed by NANJAPPAN ARAVIND
Date: 2026.08.12 18:51:35 +05'30'

AANJAAY INDUSTRIES LIMITED

Nanjappan Aravind

Managing Director

DIN: 01895602

Date: 12th August 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers
21st Floor, Dalal Street
Mumbai – 400001

BSE Scrip Code: 524322

Sub: Declaration with respect to audit report with unmodified opinion for the quarter ended on 30th June 2026.

Dear Sir/Madam,

In compliance with the provisions of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by SEBI Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 and SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby declare that the Auditor of our Company, M/s PPN & Company Chartered Accountants, have issued limited review report with unmodified opinion on Un-Audited Standalone Financial Results of the Company for the quarter ended 30th June 2026.

Kindly take the aforesaid information on record and oblige.

Thanking you,

Yours sincerely,

For Aanjaay Industries Limited

(Formerly known as Kabra Drugs Limited)

NANJAPPAN ARAVIND
Digitally signed by NANJAPPAN ARAVIND
Date: 2026.08.12 18:51:46 +05'30'

AANJAAY INDUSTRIES LIMITED

Nanjappan Aravind
Managing Director
DIN: 01895602